Search research articles
Contact Us
Filters
Showing results (131-140 of 466) with videos related to
Page
of 47
Sort By:
Neoplasia (New York, N.Y.)
|
February 21, 2026
Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148]
Teresa Schmid, Julia Maier, Melanie Martin, et al.
Blood
|
October 11, 2014
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger, Johannes Schetelig, Niels Andersen, et al.
International Journal of Cancer
|
May 16, 2014
Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6
Nupur Bhattacharya, Michaela Reichenzeller, Maiwen Caudron-Herger, et al.
Frontiers in Oncology
|
March 8, 2021
Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
Konstantinos Christofyllakis, Claudia Pföhler, Moritz Bewarder, et al.
British Journal of Haematology
|
May 28, 2011
Nurse-like cells show deregulated expression of genes involved in immunocompetence
Nupur Bhattacharya, Susanne Diener, Irina S Idler, et al.
British Journal of Haematology
|
July 2, 2019
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement
Krista Yordanova, Stephan Stilgenbauer, Rainer M Bohle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes
Dirk L Kienle, Christian Korz, Beate Hosch, et al.
British Journal of Haematology
|
January 16, 2007
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse
Mark Ringhoffer, Stephanie von Harsdorf, Michael Schmitt, et al.
Future Oncology (London, England)
|
July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Petra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.
International Journal of Cancer
|
May 9, 2022
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors
Christine Wolf, Carsten Maus, Michael R O Persicke, et al.
Page
of 47
Search research articles
Search
Showing results (131-140 of 466) with videos related to
Sort By:
Page
of 47
Neoplasia (New York, N.Y.)
|
February 21, 2026
Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148]
Teresa Schmid, Julia Maier, Melanie Martin, et al.
Blood
|
October 11, 2014
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger, Johannes Schetelig, Niels Andersen, et al.
International Journal of Cancer
|
May 16, 2014
Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6
Nupur Bhattacharya, Michaela Reichenzeller, Maiwen Caudron-Herger, et al.
Frontiers in Oncology
|
March 8, 2021
Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
Konstantinos Christofyllakis, Claudia Pföhler, Moritz Bewarder, et al.
British Journal of Haematology
|
May 28, 2011
Nurse-like cells show deregulated expression of genes involved in immunocompetence
Nupur Bhattacharya, Susanne Diener, Irina S Idler, et al.
British Journal of Haematology
|
July 2, 2019
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement
Krista Yordanova, Stephan Stilgenbauer, Rainer M Bohle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes
Dirk L Kienle, Christian Korz, Beate Hosch, et al.
British Journal of Haematology
|
January 16, 2007
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse
Mark Ringhoffer, Stephanie von Harsdorf, Michael Schmitt, et al.
Future Oncology (London, England)
|
July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Petra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.
International Journal of Cancer
|
May 9, 2022
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors
Christine Wolf, Carsten Maus, Michael R O Persicke, et al.
Page
of 47